The U.S. cancer tissue diagnostics market is estimated to increase from US$ 4.6 billion in 2026 to US$ 6.7 billion by 2033, expanding at a CAGR of 5.6% during the forecast period.

Market growth is supported by the rising adoption of precision oncology, increasing cancer diagnosis rates, and the growing importance of tissue-based biomarker testing in treatment decisions. Immunohistochemistry (IHC), in situ hybridization (ISH), molecular diagnostics, and companion diagnostics are increasingly used to characterize tumors and identify biomarkers such as HER2, PD-L1, EGFR, ALK, and other clinically relevant alterations.

U.S. hospitals, specialty cancer centers, and diagnostic laboratories are also investing in automated staining systems, digital pathology, multiplex assays, and molecular profiling platforms to improve diagnostic accuracy and turnaround times. The growing use of targeted therapies and immunotherapies, along with pharmaceutical development of biomarker-driven treatments, is further strengthening demand for tissue-based cancer testing across the U.S. oncology care pathway.

Rising Demand for Biomarker-Based Cancer Diagnosis

The growing adoption of precision oncology in the U.S. is increasing demand for tissue-based biomarker testing. IHC, ISH, molecular diagnostics, and companion diagnostics are increasingly used to classify tumors and identify biomarkers that guide treatment selection.

The expanding use of targeted therapies and immunotherapies for breast, lung, colorectal, and other cancers is further increasing the need for accurate tissue characterization. Hospitals, specialty cancer centers, and diagnostic laboratories are expanding their testing capabilities to support personalized treatment decisions, strengthening demand for cancer tissue diagnostics across the U.S. Increasing emphasis on early treatment stratification and evidence-based oncology is also encouraging physicians to incorporate tissue testing into routine diagnostic workflows.

The growing availability of biomarker-driven treatment options is further increasing the clinical value of accurate tissue testing across different stages of cancer management.

Increasing Adoption of Advanced Pathology Technologies

The integration of automated staining platforms, digital pathology, multiplex assays, and molecular profiling technologies is supporting market growth. These technologies improve testing efficiency, diagnostic accuracy, and turnaround times while enabling laboratories to evaluate multiple tumor markers from limited tissue samples. Growing adoption of whole-slide imaging and AI-assisted pathology is also improving workflow management and supporting remote collaboration among pathologists.

Continued modernization of pathology laboratories across U.S. healthcare institutions is therefore creating sustained demand for advanced tissue diagnostic products. The increasing availability of integrated pathology platforms is further helping laboratories standardize testing workflows and manage growing cancer diagnostic volumes more efficiently. Greater investment in laboratory automation is also helping healthcare providers address increasing testing workloads while maintaining consistent diagnostic quality.

Restraints - High Cost of Advanced Tissue Diagnostic Systems

High costs associated with molecular testing platforms, automated staining instruments, digital pathology systems, reagents, and specialized assays can restrict adoption, particularly among smaller hospitals and independent laboratories. Advanced tissue diagnostics also require continuous investment in equipment maintenance, software, quality control, and laboratory infrastructure. These financial requirements can make implementation challenging for facilities with limited diagnostic budgets.

Additional expenses related to laboratory upgrades, staff training, data storage, and technology integration can further increase the overall cost of implementing advanced tissue diagnostic solutions. Periodic technology upgrades and specialized consumables can further increase the long-term operating expenses associated with advanced diagnostic platforms.

Complex Testing Workflows and Skilled Workforce Requirements

Cancer tissue diagnostics require standardized tissue collection, fixation, processing, staining, and interpretation procedures to maintain reliable results. Variations in sample quality and pre-analytical handling can affect test accuracy and reproducibility. In addition, advanced molecular and digital pathology workflows require trained pathologists, laboratory technologists, and molecular specialists.

Workforce shortages and the need for ongoing technical training can increase operational complexity and slow technology adoption. The growing complexity of multi-biomarker and molecular testing also requires laboratories to maintain stringent quality-control procedures and ensure consistent interpretation across testing facilities. Managing multiple testing platforms and integrating results into existing laboratory workflows can further increase operational demands for pathology departments.

Opportunities - Expansion of AI-Enabled Digital Pathology

Increasing adoption of digital pathology and AI-assisted image analysis creates significant opportunities for diagnostic technology providers in the U.S. AI tools can support tumor classification, biomarker interpretation, image analysis, and workflow prioritization while helping pathologists manage growing testing volumes. Integration of digital pathology with laboratory information systems can also improve data accessibility and facilitate remote consultation across hospital and cancer-center networks.

As more U.S. laboratories transition from conventional microscopy to digital workflows, demand for AI-supported pathology software, whole-slide imaging systems, and image-analysis solutions is expected to increase. These technologies can also support centralized pathology networks by enabling faster case sharing, specialist review, and standardized interpretation across geographically distributed facilities.

Growing Demand for Multiplex and Comprehensive Tumor Profiling

The increasing use of targeted therapies and immunotherapies is creating opportunities for multiplex biomarker testing and comprehensive tumor profiling. Multiplex IHC and ISH can evaluate multiple biomarkers from limited tissue specimens, while molecular profiling and NGS can identify clinically relevant genomic alterations. Increasing collaboration between pharmaceutical companies and diagnostic developers for companion diagnostic development is further expanding opportunities for tissue-based testing across the U.S. oncology market.

The growing need to obtain more actionable information from limited biopsy samples is also driving adoption of integrated testing platforms that combine histological, protein, and genomic information. Expansion of personalized treatment pathways is expected to further increase demand for comprehensive tissue profiling that can support therapy selection and clinical decision-making.

By Product, Immunohistochemistry (IHC) Test Kits Lead with Broad Clinical Application

Immunohistochemistry (IHC) Test Kits are projected to account for 31.6% of the U.S. cancer tissue diagnostics market in 2026, making them the leading product segment. Their strong position is supported by widespread use in tumor classification, biomarker identification, disease characterization, and treatment selection across major cancer types. IHC testing is particularly important for evaluating clinically relevant markers such as HER2, hormone receptors, and PD-L1.

The growing adoption of targeted therapies and immunotherapies is increasing the need for reliable biomarker assessment before treatment initiation. Automated staining platforms and standardized reagent systems are also improving laboratory efficiency, reproducibility, and turnaround times. In addition, increasing integration of IHC testing with digital pathology and image-analysis technologies is supporting more efficient interpretation across U.S. hospitals, specialty cancer centers, and diagnostic laboratories. Continued expansion of precision oncology is expected to sustain demand for IHC-based tissue diagnostics.

By Application, Breast Cancer Leads Due to High Testing Volumes and Extensive Biomarker Assessment

Breast cancer is projected to represent 46.8% of the U.S. cancer tissue diagnostics market in 2026, making it the largest cancer segment. The segment benefits from substantial diagnostic testing volumes and the established role of tissue analysis in breast cancer classification and treatment planning. IHC and ISH testing are routinely used to evaluate biomarkers such as estrogen receptor (ER), progesterone receptor (PR), and HER2, which are important for determining appropriate therapeutic strategies.

Continued use of targeted and hormone-based treatments is further supporting demand for tissue-based biomarker testing. Advances in digital pathology and automated staining are improving testing consistency and laboratory productivity. Integrating pathology findings with molecular and clinical information is also strengthening the role of tissue diagnostics in personalized breast cancer management across U.S. healthcare facilities.

By End-user, Hospitals Lead Through Integrated Oncology and Pathology Infrastructure

Hospitals are projected to account for 39.4% of the U.S. cancer tissue diagnostics market in 2026, maintaining their position as the leading end-user segment. Hospitals manage high volumes of cancer patients and typically provide integrated access to pathology, surgery, oncology, radiology, and molecular diagnostic services. Their in-house laboratories support tissue processing, histopathology, IHC, ISH, and molecular testing across multiple cancer indications.

Large hospital systems are also increasingly investing in automated staining platforms, digital pathology infrastructure, and advanced biomarker testing capabilities to improve diagnostic turnaround and treatment planning. Participation in clinical trials and multidisciplinary oncology programs further contributes to tissue testing volumes. In addition, established quality-control procedures and centralized laboratory operations enable hospitals to manage complex diagnostic workflows at scale, supporting their continued dominance in the U.S. market.

West U.S. Cancer Tissue Diagnostics Market Trends and Insights

The West U.S. is estimated to account for 20.8% of the U.S. cancer tissue diagnostics market in 2026, supported by advanced healthcare infrastructure, strong biotechnology activity, and widespread adoption of precision oncology. California represents a major contributor because of its large network of academic medical centers, specialty cancer hospitals, diagnostic laboratories, and research institutions. The region has strong demand for IHC, molecular diagnostics, ISH, and companion diagnostic testing across breast, lung, colorectal, and other cancers.

High adoption of digital pathology, whole-slide imaging, laboratory automation, and AI-assisted image analysis is further supporting regional market development. Collaboration between healthcare providers, biotechnology companies, and pharmaceutical organizations is encouraging the adoption of biomarker-driven testing and comprehensive tumor profiling. Leading research institutions also support clinical validation of emerging biomarkers and diagnostic technologies. Increasing cancer-care investments and continued development of integrated pathology workflows are expected to maintain steady demand for tissue-based diagnostics across the West U.S.

Midwest U.S. Cancer Tissue Diagnostics Market Trends and Insights

The Midwest U.S. is estimated to hold a 17.3% share of the U.S. cancer tissue diagnostics market in 2026, supported by a broad network of hospitals, academic medical centers, diagnostic laboratories, and regional cancer-care facilities. The region serves a large and geographically diverse patient population, creating consistent demand for tissue-based cancer testing. IHC remains widely used for tumor classification and biomarker evaluation, while molecular diagnostics and companion testing are gaining adoption as targeted cancer therapies become more common.

Major healthcare institutions are investing in laboratory automation, digital pathology, and advanced molecular testing to improve diagnostic turnaround and support treatment planning. The expansion of centralized pathology services is also helping smaller facilities access specialized testing capabilities. Increasing emphasis on personalized medicine and multidisciplinary cancer care is encouraging greater integration between pathology and oncology departments. Continued modernization of diagnostic infrastructure, together with rising demand for accurate biomarker identification, is expected to support steady growth of the cancer tissue diagnostics market across the Midwest.

Southwest U.S. Cancer Tissue Diagnostics Market Trends and Insights

The Southwest U.S. is projected to represent approximately 16.4% of the U.S. cancer tissue diagnostics market in 2026 and is expected to be among the fastest-growing regional markets during the forecast period. Population growth, expanding healthcare infrastructure, and increasing investment in oncology services are strengthening demand for advanced tissue diagnostics. Texas is a major contributor, with large hospital networks, cancer centers, academic institutions, and diagnostic laboratories expanding their pathology capabilities. Growing cancer-care capacity is increasing demand for histopathology, IHC, molecular diagnostics, and companion diagnostic testing.

Healthcare providers are also adopting digital pathology and automated laboratory systems to improve workflow efficiency and manage increasing diagnostic volumes. Expansion of specialty cancer centers is creating additional opportunities for advanced biomarker testing and comprehensive tumor profiling. Increasing use of targeted therapies and immunotherapies is further supporting molecular and tissue-based testing. As oncology infrastructure continues to expand across the region, the Southwest is expected to benefit from rising diagnostic volumes and increasing adoption of precision oncology technologies.

Southeast U.S. Cancer Tissue Diagnostics Market Trends and Insights

The Southeast U.S. is estimated to account for 22.1% of the U.S. cancer tissue diagnostics market in 2026, making it one of the largest regional contributors. Market demand is supported by a substantial patient population, rising cancer-care needs, and the expansion of hospital and specialty diagnostic infrastructure. Florida, Georgia, North Carolina, and surrounding states are developing broader oncology networks and investing in advanced pathology services. IHC, ISH, and molecular diagnostics are increasingly incorporated into cancer diagnostic workflows to support tumor classification and biomarker-driven treatment selection. Hospitals and diagnostic centers are also expanding access to digital pathology, automated staining, and molecular profiling platforms.

The growing use of targeted therapies and immunotherapies is increasing demand for biomarker testing across lung, breast, colorectal, and other cancers. Regional healthcare providers are strengthening multidisciplinary cancer programs and centralized laboratory capabilities to improve testing efficiency. Continued investments in specialty oncology facilities and advanced diagnostic technologies are expected to support sustained market expansion throughout the Southeast U.S.

Northeast U.S. Cancer Tissue Diagnostics Market Trends and Insights

The Northeast U.S. is estimated to hold the largest regional share at 23.4% of the U.S. cancer tissue diagnostics market in 2026. The region's leading position is supported by a high concentration of renowned cancer centers, academic medical institutions, reference laboratories, and specialized pathology networks. States including New York, Massachusetts, Pennsylvania, and New Jersey contribute substantially to regional demand through established oncology and research infrastructure.

The Northeast demonstrates strong utilization of IHC, ISH, molecular diagnostics, companion diagnostics, and comprehensive tumor profiling. Major healthcare institutions also widely adopt advanced digital pathology and laboratory automation, supporting faster turnaround and standardized diagnostic workflows. Extensive clinical research and pharmaceutical activity further encourage biomarker discovery and development of companion diagnostic applications. The region's strong emphasis on precision medicine and multidisciplinary cancer management continues to generate high tissue-testing volumes. As the leading U.S. region, the Northeast is expected to remain a major center for advanced cancer tissue diagnostics and precision oncology through 2033.

The U.S. cancer tissue diagnostics market is characterized by intense competition among established diagnostic and life sciences companies, including F. Hoffmann-La Roche Ltd., Danaher Corporation, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Abbott Laboratories, and Becton, Dickinson and Company (BD). These companies are strengthening their market presence through broad oncology diagnostic portfolios, established laboratory networks, companion diagnostic capabilities, and continued innovation in immunohistochemistry (IHC), in situ hybridization (ISH), molecular diagnostics, and digital pathology.

Increasing demand for precision oncology and biomarker-guided treatment is encouraging companies to expand automated staining platforms, molecular testing solutions, AI-assisted image analysis, and integrated pathology workflows. Strategic collaborations, product launches, laboratory automation, and investments in advanced tissue profiling are further shaping competitive strategies. As U.S. healthcare providers prioritize faster, standardized, and reproducible cancer diagnosis, leading companies are focusing on technologies that improve testing efficiency, biomarker identification, and clinical decision-making across hospitals, specialty cancer centers, and diagnostic laboratories.

Key Industry Developments:

• In March 2026, diagnostics company Droplet Biosciences announced a collaboration with Nvidia to leverage the chipmaker’s AI-driven computing infrastructure to accelerate post-surgical cancer testing turnaround times. As part of the partnership, Droplet Biosciences is utilizing Nvidia Parabricks, a GPU-enabled genomic analysis platform, to significantly enhance the speed and efficiency of DNA sequencing data processing, enabling faster and more precise interpretation of tumor genomic profiles.
• In March 2026, Myriad Genetics, Inc. a prominent provider of molecular diagnostics and precision medicine solutions, announced the introduction of its Precise MRD™ assay. The company is initiating deployment of the test in collaboration with a selected group of oncology practices to support molecular residual disease monitoring in patients diagnosed with breast cancer.
• In February 2026, Illumina, Inc. reported significant customer advancements in oncology enabled by its spatial transcriptomics, 5-base sequencing, and proteomics platforms. By integrating multiple omics layers, researchers can achieve deeper biological characterization and enhanced molecular resolution. These capabilities are unified through Illumina Connected Multiomics, which streamlines multimodal data interpretation. The comprehensive technology portfolio is facilitating improved precision diagnostics, accelerating development of targeted therapies, and advancing understanding of complex tumor microenvironments.
• In November 2025, Abbott Laboratories and Exact Sciences announced a definitive agreement under which Abbott will acquire Exact Sciences to strengthen its presence in rapidly expanding cancer diagnostics categories and broaden patient access. According to the transaction terms, Exact Sciences shareholders will receive $105 per common share, valuing the company at approximately $21 billion in total equity.